Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential

Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML - Pharmaceutical Technology

The deal will see MSD aim to augment and diversify its oncology portfolio via the addition of Terns’s lead candidate, TERN-701, for CML.

Merck acquisition brings Terns CML treatment into pipeline

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including an experimental treatment for chronic myeloid leukemia (CML). The acquisition will give Merck access to Terns’ lead candidate, TERN-701, an oral therapy under development for certain people with CML, a type of blood cancer characterized by the overproduction of abnormal white blood cells. The companies expect to close the acqu…

Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential

Merck & Co., Inc. (NYSE:MRK) held an investor event to discuss its planned acquisition of Terns Pharmaceuticals, emphasizing the strategic rationale, clinical data to date for Terns’ lead asset, and the financial terms of the deal. Deal rationale centers on TERN-701 and Merck’s hematology ambitions Chief Executive Officer Rob Davis said Merck’s “science-led strategy” includes […]